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Alterations in serum kynurenine
pathway metabolites in individuals
with high neocortical amyloid-β
load: A pilot study
Pratishtha Chatterjee1,2, Kathryn Goozee 1,2,3,4,5,7, Chai K. Lim1, Ian James8, Kaikai Shen9,
Kelly R. Jacobs1, Hamid R. Sohrabi1,2,5,6, Tejal Shah1,2,6, Prita R. Asih3,10, Preeti Dave1,4,
Candice ManYan4, Kevin Taddei2,6, David B. Lovejoy1, Roger Chung1, Gilles J. Guillemin 1 &
Ralph N. Martins1,2,3,5,6,7
The kynurenine pathway (KP) is dysregulated in neuroinflammatory diseases including Alzheimer’s
disease (AD), however has not been investigated in preclinical AD characterized by high neocortical
amyloid-β load (NAL), prior to cognitive impairment. Serum KP metabolites were measured in
the cognitively normal KARVIAH cohort. Participants, aged 65–90 y, were categorised into NAL+
(n = 35) and NAL− (n = 65) using a standard uptake value ratio cut-off = 1.35. Employing linear
models adjusting for age and APOEε4, higher kynurenine and anthranilic acid (AA) in NAL+ versus
NAL− participants were observed in females (kynurenine, p = 0.004; AA, p = 0.001) but not males
(NALxGender, p = 0.001, 0.038, respectively). To evaluate the predictive potential of kynurenine or/and
AA for NAL+ in females, logistic regressions with NAL+/− as outcome were carried out. After age and
APOEε4 adjustment, kynurenine and AA were individually and jointly significant predictors (p = 0.007,
0.005, 0.0004, respectively). Areas under the receiver operating characteristic curves were 0.794 using
age and APOEε4 as predictors, and 0.844, 0.866 and 0.871 when kynurenine, AA and both were added.
Findings from the current study exhibit increased KP activation in NAL+ females and highlight the
predictive potential of KP metabolites, AA and kynurenine, for NAL+. Additionally, the current study
also provides insight into he influence of gender in AD pathogenesis.
The main physiological roles of tryptophan metabolism are to generate serotonin and melatonin and also, the
essential co-factor nicotinamide adenine dinucleotide (NAD+) through the kynurenine pathway (KP) (Fig. 1).
In neuroinflammatory conditions, the KP is strongly up regulated leading to the production of several neuroactive metabolites that can be either neuroprotective, neurotoxic or immuno-modulatory. It has previously been
demonstrated that the KP is activated in several neurodegenerative and neuropsychiatric disorders including
Alzheimer’s disease (AD)1–6.
Interestingly, this central dysregulation of the KP homeostasis also manifests in the blood in AD patients7–9.
Higher ratios of KP metabolites, kynurenine (KYN) to tryptophan (K:T) in serum and plasma have been reported
in patients with AD and mild cognitive impairment (MCI)10,11 and this ratio (K:T) also inversely correlated with
cognitive performance10. Further, a decline in plasma and erythrocyte concentrations of the KP metabolite
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Figure 1. Schematic diagram of the kynurenine pathway. Tryptophan can be utilised for protein synthesis
or serotonin and melatonin production. However, over 90% peripheral tryptophan has been reported to be
metabolised via the kynurenine pathway (KP) in mammals. In the KP, tryptophan is metabolised into N-formylkynurenine followed by kynurenine (KYN) catalysed by enzymes indoleamine deoxygenase or tryptophan
deoxygenase and formamidase. KYN is then converted to kynurenic acid (KYNA) by enzyme kynurenine
aminotransferase. Alternatively, KYN is metabolised to anthranilic acid (AA) and 3-hydroxykynurenine (3HK) by enzymes kynureninase and kynurenine-3-monooxygenase, respectively. AA and 3-HK further get
metabolised to 3-hydroxyanthranilic acid (3-HAA), which in turn gets converted to aminocarboxymuconic
semialdehyde (ACMA). ACMA spontaneously converts to neurotoxin, quinolinic acid, a substrate for the redox
agent, NAD+. Alternatively, ACMA can be assisted by enzyme 2-amino-3-carboxymuconatesemialdehyde
decarboxylase to generate picolinic acid. KP metabolites marked in bold, have been investigated in the current
study.

kynurenic acid (KYNA), which is produced via a secondary branch of the KP and precludes NAD+ production
from KYN, has been reported in patients with AD and MCI11,12. Furthermore, elevated plasma levels of the excitotoxin quinolinic acid, have been reported in AD7. Additionally, a relatively recent study reported an association
between dementia risk and elevated plasma levels of the KP metabolite, anthranilic acid (AA)13.
However, KP metabolite alterations have never been investigated in the preclinical stage of AD that is characterised by high neocortical amyloid-β load (NAL)14 measured via positron emission tomography (PET), prior
to cognitive decline, given that the deposition of NAL begins to occur two to three decades prior to the clinical
manifestation of the disease15.
Therefore, the current pilot study investigated whether the dysregulation of the KP occurs within the preclinical stage of the AD pathogenesis trajectory, in cognitively normal individuals. Serum tryptophan and KP metabolites, primarily comprising, KYN, KYNA, 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA),
AA, picolinic acid and quinolinic acid, were hence measured in, and compared between, cognitively normal
individuals with preclinical AD characterised by high NAL (NAL+; standard uptake value ratio (SUVR) ≥1.35)
and individuals with no apparent risk to AD, characterised by low NAL (NAL−, SUVR <1.35)16–18.

Results

Comparison of demographic characteristics between NAL− and NAL+ participants.

Demographic characteristics of study participants have been presented in Table 1 (and demographic characteristics stratified by gender are available in Supplementary Table 1). As expected, the APOE ε4 carriage frequency was
significantly higher in NAL+ participants (45.7%) compared to NAL− participants (7.7%)18–20. No significant
differences were observed in age, gender, body mass index, MMSE scores, MoCA scores, years of education, sex
hormone levels and hippocampal volume between NAL− and NAL+ cohort participants (Table 1).

KP metabolites and the three major AD risk factors i.e. age, APOE ε4 carriage and gender.

When the association between KP metabolites and AD risk factors were investigated, among the KP metabolites,
quinolinic acid positively correlated with age (p < 0.05, Supplementary Table 2), while no significant differences
in KP metabolites were observed with respect to APOE ε4 carriage (Supplementary Table 3). However, significantly higher concentrations of KP metabolites, KYNA and 3-HAA, were observed in males compared to females,
uncorrected and corrected for covariates age and APOE ε4 status (p ≤ 0.005, Supplementary Table 4).
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NAL−

NAL+

p

Gender (M/F)

19/46

13/22

0.419

Age (years, mean ± SD)

77.61 ± 5.55

79.22 ± 5.38

0.165

BMI (mean ± SD)

27.38 ± 4.47

28.05 ± 4.73

0.486

nAPOE ε4 carriers (%)

5 (7.7)

16 (45.7)

<0.0001

MMSE (mean ± SD)

28.50 ± 1.16

28.80 ± 1.10

0.225

MoCA (mean ± SD)

27.43 ± 1.67

27.03 ± 1.92

0.278

Education (years, mean ± SD)

14.84 ± 3.37

13.64 ± 2.91

0.078

Testosterone (nmol/L, mean ± SD), males

14.43 ± 6.16

11.66 ± 3.77

0.160

Testosterone (nmol/L, mean ± SD), females

1.45 ± 2.55

1.26 ± 0.81

0.738

Oestradiol (pmol/L, mean ± SD), males

113.16 ± 47.83

117.23 ± 35.17

0.795

Oestradiol (pmol/L, mean ± SD), females

91.22 ± 118.71

73.90 ± 28.97

0.523

FBB-PET SUVR (mean ± SD, n = 100)

1.15 ± 0.08

1.71 ± 0.26

—

HV% (left; right lobes, mean ± SD, n = 96)

0.195 ± 0.020;
0.199 ± 0.021

0.194 ± 0.019;
0.199 ± 0.018

0.805; 0.890

Table 1. Demographic characteristics of cohort participants. Baseline characteristics including gender, age,
body mass index (BMI), APOE ε4 status, mini mental state examination (MMSE) scores, Montreal Cognitive
Assessment (MoCA, adjusted for education) scores, years of education, sex hormone levels, neocortical amyloid
load (NAL) represented by the standard uptake value ratio (SUVR) of ligand 18F-Florbetaben (FBB) in the
neocortical region normalised with that in the cerebellum, and hippocampal volume (HV) normalised by the
intracranial volume, have been compared between NAL− (SUVR <1.35) and NAL+ (SUVR ≥1.35) study
participants. Chi-square test or linear models were employed as appropriate. Ninety-six participants underwent
MRI (nNAL− = 64, nNAL+ = 32).

KP metabolites and NAL. Serum kynurenine and anthranilic acid levels were significantly elevated in
NAL+ versus NAL− participants uncorrected and corrected for age, gender, APOE ε4 status and education
(Supplementary Table 5). However, on comparing KP metabolites between NAL− and NAL+ cohort participants, after adjustment for age, gender and APOE ε4 status, there were significant differences between the associations of metabolites and NAL+/− according to gender for KYN (p = 0.001), 3- HK (p = 0.001), AA (p = 0.038)
and QA (p = 0.007). In particular, KYN was significantly higher for NAL+ vs NAL− in females (p = 0.004), but
not significantly different in males; 3-HK was higher for NAL+ vs NAL− in females (p = 0.017) but lower in
males (p = 0.022); and AA was higher for NAL+ vs NAL− in females (p = 0.001) but not for males. QA showed
a tendency to increase for NAL+ vs NAL− in females and to decrease in males, but neither were individually
significant (Fig. 2, Supplementary Table 6, demographics available in Supplementary Table 1). Additionally, given
the complex interaction between KP metabolites and that the generation of KYNA precludes the formation of AA
given their common precursor (KYN, see Fig. 1), we also investigated K:T and AA:KYNA ratios, wherein both
were observed to be significantly higher in NAL+ versus NAL− female participants (Supplementary Table 6).
While no correlation between NAL (as a continuous variable) and KP metabolites were observed in male participants, NAL significantly correlated with KYN and AA without adjusting for covariates (Fig. 3) and KYN, AA,
3-HK and 3-HAA after correcting for covariates age and APOE ε4 status in female participants (Supplementary
Table 7). The observation of 3-HAA significantly correlating with NAL in the females, but not being significantly elevated in NAL+ versus NAL− for this gender (Supplementary Table 6) can be attributed to the fact
that 3-HAA correlated with NAL (correcting for age and APOE ε4 status) only within the NAL+ female subset
(n = 22, ra = 0.572, pa = 0.008).
Potential of KP metabolites to predict NAL+. Given that significantly elevated KYN and AA concentrations, in particular, were observed in NAL+ (versus NAL−) female sera we evaluated these and other
metabolites as potential markers in females to predict NAL+ via logistic regression with NAL+/− as response.
After adjusting for age and APOE ε4 status, all metabolites were entered jointly (on the log scale) and backward
elimination was used to obtain the simplest model containing only significant terms. Only KYN (p = 0.03) and
AA (p = 0.045) remained jointly significant (joint p = 0.0004). A ‘base’ model incorporating the major risk factors for AD, age and APOE ε4 allele status, was then generated and compared to the ‘base+ KYN’, ‘base+ AA’
and ‘base+ KYN+ AA’ models, wherein either KYN, AA or both KYN and AA concentrations were added to
the base model (Fig. 4). The area under the curve (AUC) of the ‘base+ KYN’ (AUC = 0.843, specificity = 52% at
sensitivity = 90%, log(KYN) p = 0.007), ‘base+ AA’ (AUC = 0.865, specificity = 83% at sensitivity = 90%, log(AA)
p = 0.005) and ‘base+ KYN+ AA’ model (AUC = 0.87, specificity = 65% at sensitivity = 90%) outperformed the
‘base’ model (AUC = 0.794, specificity = 43% at sensitivity = 90%) in distinguishing NAL+ from NAL− participants. While it is marginally significant on its own as an additional predictor for NAL+, the K:T ratio is not
significant when AA is already included (p = 0.47).

Discussion

In mammals, the KP has been reported to account for over 90% of peripheral tryptophan catabolism21. Our
findings exhibit aberrant peripheral tryptophan metabolism, via the KP, in preclinical AD wherein, significantly
elevated KYN, AA and 3-HK serum concentrations were present in NAL+ versus NAL− females. Additionally,
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Figure 2. Comparison of kynurenine pathway metabolites between NAL− and NAL+ participants, separately
in males and females. Kynurenine pathway metabolite concentrations in serum were compared between
participants (in A. Males and B. Females, separately) with neocortical amyloid-β load (NAL, assessed by
the standard uptake value ratio observed via positron emission tomography using ligand 18F-florbetaben)
<1.35 (NAL−) and ≥1.35 (NAL+) using linear models. Kynurenine (KYN), anthranilic acid (AA) and
3-hydroxykynurenine (3-HK) levels were significantly higher in NAL+ (N = 22) compared with NAL−
(N = 46) female participants while 3-hydroxykynurenine (3-HK) levels were significantly lower in NAL+
(N = 13) compared with NAL− (N = 19) male participants. The line segment within each box plot represents
the median within each box plot and error bars represent the range of the metabolite concentration for each
group. *Represents p < 0.05, **represents p ≤ 0.01 and ***represents p < 0.0005; p values were obtained from
variables transformed to the logarithmic scale for analyses to meet assumptions of the statistical test employed.
TRP, tryptophan; KYNA, kynurenic acid; HAA, 3-hydroxyanthranilic acid; PA, picolinic acid; QA, quinolinic
acid. (A) Serum metabolite concentrations in males. (B) Serum metabolite concentrations in females.

within female study participants, a significant positive correlation was observed between NAL and the aforementioned serum KP metabolite concentrations.
Similar to findings in the current preclinical AD study, elevated serum KYN concentrations and K:T ratios
have been reported previously in clinical AD and in individuals with MCI10,11. The foremost step in the KP i.e. the
generation of KYN from tryptophan, via N-formyl-KYN, is catalysed by enzymes indoleamine 2,3-dioxygenase
1(IDO1; predominantly expressed in extra-hepatic cells such as neurons, macrophages, microglia and astrocytes)
or tryptophan 2,3-dioxygenase (TDO; predominantly expressed in hepatocytes)22–25. Significantly higher IDO1
and TDO immunoreactivity has been reported in AD patient hippocampi3,26. Further, IDO1 and TDO, have been
reported to be regulated by immune system signalling molecules, growth factors and steroids1,22,27,28, all of which
SCIENTIFIC RePortS | (2018) 8:8008 | DOI:10.1038/s41598-018-25968-7
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Figure 3. Correlation between NAL and KP metabolites, KYN and AA, in females. Significant correlations
were observed between neocortical amyloid-β load (NAL) and serum concentrations of (A) kynurenine (KYN;
r = 0.346, p = 0.004, n = 68) (B) anthranilic acid (AA; r = 0.449, p = 0.0001, n = 68) using Pearson’s correlation
coefficient (r), in females. Correlation coefficients after adjusting for covariates age and APOEε4 are available
in Supplementary Table 6. Serum KYN and AA concentrations were transformed to the logarithmic scale for
analyses, to meet assumptions of the statistical test employed.
have been shown to be associated with AD pathogenesis29–33. Our findings of elevated serum KYN concentrations
along with higher K:T ratios in NAL+ versus NAL− participants together with the afore cited literature are therefore indicative of increased tryptophan degradation via the KP, from the preclinical stages of the AD pathogenesis
trajectory, prior to cognitive impairment.
Given the observation of significantly increased KP activation in NAL+ participants, apparent from the elevated serum KYN concentrations and K:T ratios in NAL+ (female) participants within the current study, further
investigation of downstream KP metabolites revealed elevated AA serum concentrations in females. This observation is further corroborated by a study conducted by Chouraki and colleagues that reported elevated serum AA
concentrations in cognitively normal individuals who later developed dementia13. However, AA concentrations
were not reported to be significantly elevated in a study examining KP metabolites in clinical AD7. Taken together
with the findings of Chouraki and colleagues, we specifically demonstrate elevated AA levels as a feature of NAL+
preclinical AD that is predictive of converting to clinical AD. However, our study shows a strong gender effect,
namely in females.
Additionally, it is important to note that even though both precursors to 3-HAA (AA, 3-HK) are elevated in
NAL+ females, 3-HAA itself is not elevated in NAL+ females. Interestingly, Chouraki and colleagues reported a
trend of association between plasma 3-HK and decreased risk of incident dementia, even though plasma anthranilic acid levels were observed to be associated with increased risk of incident dementia13. One possible explanation could be that the enzyme (activity) that catalyses the production of 3-HAA is decreased in NAL+, however,
further studies are required to investigate this notion.
While the influence of gender on serum KP metabolite concentrations has been reported previously34, to our
knowledge, no previous study has reported significantly elevated KYN (or K:T ratio) or/and AA or/and 3-HK
restricted to the female population, in AD pathogenesis, as observed within the current study. It is however
acknowledged that the current cohort may have lacked sufficient power within the male subset given its modest sample size (19 NAL− males/13 NAL+ males). Three-HK was observed to significantly increase in NAL+
females compared to NAL− females but decrease in NAL+ males compared to NAL− males. While the mechanism behind these observations are currently not known, our results further exhibit the strong gender difference
in AD pathogenesis (Supplementary Table 6). Schwarz and colleagues reported elevated 3-HK serum concentrations in AD, which support our findings in preclinical female participants. Interestingly, the clinical AD group in
the study by Schwarz and colleagues comprised 80% females (16 females/4 males)8. Given the paucity of literature
describing the impact of gender on the relationship between AD pathology and 3-HK and particularly the relatively small sample size of males in both studies, further investigations are warranted on KP metabolite alterations
in AD pathogenesis, in larger male and female cohorts.
Further, the current study observed a strong interaction effect between NAL and gender on KP metabolites
that may be attributed to the influence of sex hormones on the enzymes involved within the KP35. For example,
testosterone has been reported to have an inhibitory effect on the KP (via TDO/IDO1 by reducing NAD production in favour of KYNA formation)36,37 while oestrogen has been reported to induce (via TDO/IDO1 favouring
NAD+ production, precluding KYNA formation)38 as well as inhibit the KP (by inhibiting immune system activation)39. However, the incidence of ageing-related hormonal changes prevalent within the KARVIAH cohort and
the complex interplay and feedback mechanisms between the various KP metabolites also need to be considered
with regard to observations in this study. Within the current study, it may be posited that elderly women were
more vulnerable (NAL+ vs NAL−) to increased KP activity compared to elderly men, given the postmenopausal
plummet in oestrogen which increases vulnerability to AD, while in similarly aged men40, testosterone levels are
relatively stable which may confer neuroprotection32,33,41–45.
In addition to the influence of the sex hormones, other mechanisms resulting in increased KP activation
contributing to AD pathogenesis may also be involved. Given that inflammation is an early feature in the AD
pathogenesis trajectory, inflammation induced immune responses occurring in AD pathogenesis, may upregulate IDO activity and tryptophan degradation resulting in increased KP activation46,47. Although the current
study addresses the peripheral concentrations of KP metabolites, blood concentrations of tryptophan, KYN, AA
SCIENTIFIC RePortS | (2018) 8:8008 | DOI:10.1038/s41598-018-25968-7
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Figure 4. Receiver operating characteristic (ROC) curves for the prediction of high neocortical amyloid-β
load in female participants. The ‘base’ model comprising major risk factors age and APOE ε4 allele status (A)
was outperformed by the ‘base+ kynurenine’ model (B) and the ‘base+ anthranilic acid’ model (C) and ‘base+
kynurenine+ anthranilic acid’ model (D). Logistic regression models were employed to perform the analyses.
AUC: area under the curve.

and 3-HK significantly contribute to the brain pools of these metabolites (~60%), given their permeability to the
blood brain barrier48,49. Therefore, elevated KYN, AA and 3-HK in NAL+ serum may consequently enhance
KYN, AA and 3-HK concentrations in NAL+ brains. Given that the two branches of the KP occur in a segregated manner in the brain, wherein 3-HK and its further downstream metabolites occur in the microglia (while
KYNA is formed in the astrocytes)25, we posit that an increase in KP intermediate substrates impact microglial
activation inducing secretion of inflammatory signalling molecules. This inflammation could further induce Aβ
generation, in turn triggering further inflammation, resulting in a vicious cycle50. Aβ has been reported to induce
interferon-γ51, a potent activator of IDO52, resulting in increased KP activity53, further leading to elevated concentrations of KYN and its downstream metabolites, such as AA. It could be argued that elevations in AA concentrations in NAL+ versus NAL− may actually represent a protective mechanism against AD pathogenesis due to
the presence of iron dyshomeostasis in preclinical AD17,54, given that AA is known to have reactive oxygen species
scavenging properties by iron chelation55.
The current pre-mortem gold standard biomarkers for preclinical AD, namely NAL measured via PET
(employed within the current study) and cerebrospinal fluid (CSF) concentrations of Aβ42 and tau, are uneconomical and invasive, respectively. Therefore, we also evaluated the KP metabolite alterations observed within
the present study as potential blood biomarkers for preclinical AD or NAL+ . We found significant KP metabolite
alterations that reflect NAL positivity in females. Interestingly, the addition of AA to a base model comprising age
and APOE ε4 allele status, resulted in an increased specificity from 43% to 83%, at a sensitivity of 90%, indicating
that AA may serve as a statistically significant predictor of NAL over and above the base model, in elderly females.
We acknowledge that the current study has limitations such as the cross-sectional nature of the study and the
relatively modest sample size of the cohort whereby the male subset may have lacked sufficient power, contributing to the absence of significant KP metabolite alterations observed in the female cohort subset. However, given
that sex hormones play an important role in regulating the KP, it is highly likely that the findings in our study
will be replicated in a larger cohort. Additionally, given the modest sample size and pilot nature of the study,
we have not corrected for multiple testing. However, our findings of significantly elevated KYN and AA levels
in NAL+ females compared to NAL− females remain significant following Bonferroni correction for multiple
testing (KYN, p = 0.03; AA, p = 0.01). Furthermore, although KYN and AA significantly add to the predictive
potential of the base model comprising the three major risk factors of AD (namely age, APOE ε4 and gender) for
NAL+, further confirmatory studies are required.
Finally, to conclude, the current study reports KP metabolite alterations in preclinical AD (characterised
by high NAL) females wherein, serum concentrations of KYN, AA and 3-HK were elevated prior to cognitive impairment and hippocampal atrophy. To our knowledge, this is also the first study to report an association between concentrations of the aforementioned metabolites with NAL, a gold standard biomarker of AD.
Importantly, the current study also identifies potential blood biomarkers for preclinical AD. Interestingly, our
findings were restricted to the female subset of the cohort, which may provide further insight into the gender
effects in AD pathogenesis. While our observations could be attributed to the several mechanisms hypothesised
above, further validation studies are warranted. Given the preliminary nature of the current findings, confirmation in a larger sample set is required. Additionally, future studies are also required to measure the KP enzyme
activities, in addition to employing male predominant cohorts and longitudinal studies, to gain further insight
into these current findings.

Methods and Materials

Participants. Study participants were from the Kerr Anglican Retirement Village Initiative in Ageing Health
(KARVIAH) cohort, at baseline. All participants were residents of Anglicare, New South Wales, Australia.
Cohort volunteers (N = 206) were screened for the inclusion and exclusion criteria of the KARVIAH cohort17.
The inclusion criteria for the KARVIAH Study briefly comprised, an age range of 65–90 years, good general
health, no known significant cerebral vascular disease, fluent in English, adequate/corrected vision and hearing to enable testing, no objective cognitive impairment measured using a Montreal Cognitive Assessment
(MoCA) cut-off score ≥2656. MoCA scores lying between 18–25 were assessed on a case by case basis by the
study neuropsychologist following stratification of scores according to age and education norms57. The exclusion
SCIENTIFIC RePortS | (2018) 8:8008 | DOI:10.1038/s41598-018-25968-7
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criteria comprised, the diagnosis of dementia based on the revised criteria from the National Institute on Aging Alzheimer’s Association58, presence of acute functional psychiatric disorder (including lifetime history of schizophrenia or bipolar disorder), history of stroke, severe or extremely severe depression (based on the depression,
anxiety, stress scales; DASS) and uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100).
One hundred and five participants out of the 134 volunteers meeting the inclusion/exclusion criteria, underwent neuroimaging, neuropsychometric evaluation and blood collection, as the remaining either declined neuroimaging or withdrew from the study. Within these 105 participants, 100 participants were considered to be
cognitively normal based on their Mini-Mental State Examination score59 (MMSE ≥26), and were included in
the current study. Concentrations of the KP metabolites in the serum were reported in all 100 participants with
MMSE ≥26. All experimental protocols were approved by the Bellberry Human Research Ethics Committee,
Australia and were performed in accordance with the relevant guidelines and regulations. The study volunteers
provided written informed consent prior to participation, and the Bellberry Human Research Ethics Committee,
Australia, provided ethical approval for the study.

Evaluation of neocortical amyloid-β load and hippocampal volumes via PET and MRI.

Study
participants were imaged within three months of blood collection. Participants underwent positron emission
tomography (PET) using ligand 18F-Florbetaben (FBB), and magnetic resonance imaging (MRI) at Macquarie
Medical Imaging in Sydney.
All 100 participants within the current study underwent FBB-PET. Participants were administered an intravenous bolus of FBB slowly over 30 s, while in a rested position. Images were acquired over a 20 min scan, in 5 min
acquisitions, beginning 50 min post injection. Neocortical amyloid load was calculated as the mean SUVR of the
ligand FBB in the frontal, superior parietal, lateral temporal, lateral occipital, and anterior and posterior cingulate
regions normalised with that in the cerebellum using image processing software, CapAIBL60,61.
Ninety-six of the 100 participants within the current study passed all standard MRI inclusion/exclusion criteria, and underwent MRI as described previously using a General Electric (GE) 3Tesla scanner (Model 750 W)16.
Hippocampal volume calculated from the images acquired was normalized with the total intracranial volume
comprising the cerebrospinal fluid, grey matter and white matter.

Blood collection and processing, and measurement of KP metabolites in serum. All study participants fasted for a minimum of 10 hours overnight prior to blood collection employing standard serological
methods and processing techniques for serum collection as described previously17,20. Serum samples were collected in the year 2015 and stored at −80 °C until thawed for measurement of KP metabolites in the year 2017.
All reagents and KP metabolite standards were analytical reagent grade and were purchased from
Sigma-Aldrich (St Louis, MO), unless otherwise stated. Deuterated internal standards were purchased from
Medical Isotopes, Inc (Pelham, NH). Serum samples were prepared for KP metabolite analyses with the addition
of equal volumes of 10% (w/v) trichloroacetic acid (TCA).
Analyses of tryptophan, KYN, 3-HK, 3-HAA and AA were performed simultaneously with ultra high performance liquid chromatography (UHPLC) with an injection volume of 20 μL per sample, as described previously46.
KYNA separation was carried out following injection (10 µL) onto a Poroshell RRHT C-18, 1.8μm 2.1 × 100 mm column (Agilent Technologies, Inc, Santa Clara, CA) and quantified via fluorescence detection (excitation and emission
wavelengths of 344 nm and 388 nm, respectively; retention time 1.5 min). A gradient method with 50 mM sodium
acetate, 25 mM zinc acetate and 2.25% acetonitrile (Eluent A), and 10% acetonitrile (Eluent B) was employed and
separation was performed at 38 °C with a flow rate of 0.75 mL/min. Separation achieved over 10 min, comprised
100% eluent A for 3 min, 50% eluent A for 2 min, 0% eluent A for 2 min and re-equilibration with 100% eluent A for
3 min. Data were analysed with the Agilent OpenLAB CDS ChemStation (Edition C.01.04).
For gas chromatography coupled with mass spectrometry (GCMS), 50 μL of sample extract was derivatized.
Simultaneous analysis of picolinic acid and quinolinic acid were performed as described previously62 with minor
modifications using an Agilent 7890 A GC system coupled with Agilent 5975 C mass spectrometry detector and
Agilent 7693 A autosampler (Agilent Technologies, Inc, Santa Clara, CA) with one microliter of derivatized mixture. Separation of picolinic acid and quinolinic acid were achieved with a DB-5MS column, 0.25μm film thickness, 0.25 mm × 30 m capillary column (Agilent Technologies, Inc, Santa Clara, CA) within 7 min but the assay
run time was set for 12 min to prevent sample carryover. Picolinic acid and quinolinic acid concentrations were
analysed using Agilent GC/MSD ChemStation software (Edition 02.02.1431) and interpolated from the established six-point calibration curves based on the abundance count ratio of the metabolites to their corresponding
deuterated internal standards within each standard and sample. The intra- and inter-assay CV was within the
acceptable range (4–8% for UHPLC assays, 7–10% for GCMS assays) calculated from the repeated measures of
the metabolite standards incorporated during the sequence run.
APOE genotyping. Apolipoprotein E (APOE) genotype was determined from purified genomic DNA
extracted from 0.5 ml whole blood, wherein each sample was genotyped for the presence of the ε2, ε3, and ε4
APOE variants based on TaqMan SNP genotyping assays for rs7412 (C 904973) and rs429358 (C 3084793) as per
the manufacturer’s instructions (AB Applied Biosystems by Life Technologies, Victoria, Australia).
Statistical analyses. Descriptive statistics including means and standard deviations or proportions were
calculated for NAL+ and NAL− groups, with comparisons employing t-tests or Chi-square tests as appropriate
in Table 1. Linear models were employed to compare continuous variables (KP metabolites) between categories
corrected for covariates age, gender, APOE ε4 carrier status and years of education. Response variables were
log transformed as necessary to better approximate normality and variance homogeneity. Differences in association of the KP metabolites with NAL+/− for females and males were assessed by incorporation of gender
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by NAL interactions into the models. Pearson correlations (r) and partial correlations (ra, adjusting for age and
APOE ε4 carrier status and rb, adjusting for age, APOE ε4 carrier status and education) were employed to evaluate the strength of the association between KP metabolites and neocortical Aβ deposition. Logistic regression
with NAL−/+ as response was used to evaluate predictive models and receiver operating characteristic curves
constructed from the logistic scores. All analyses were carried out using IBM SPSS Version 23 and receiver
operating characteristic (ROC) curves were generated using the package Deducer on R (version 3.2.5). The datasets generated and analysed during the current study are available from the corresponding author on reasonable
request.
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